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ABSTRACT 
Background 
High false positive rates and the subsequent cost of additional investigations provide 
a major obstacle to screening young athletes for cardiac disease with an 
electrocardiogram (ECG). However, the actual cost of ECG screening has never 
been assessed systematically in a large cohort of athletes. 
Objective 
This study investigated the financial implications associated with ECG interpretation 
in athletes according to the 2010 European Society of Cardiology (ESC) and the 
more contemporary Seattle and refined ECG interpretation criteria. 
Methods 
Between 2011 and 2014, 4,925 previously unscreened athletes aged 14-35 years 
were prospectively evaluated with history, physical examination and an ECG 
interpreted with the 2010 ESC recommendations. Athletes with abnormal results 
underwent secondary investigations, the costs of which were based on the UK 
National Health Service Tariffs. The impact on cost after applying the Seattle and 
refined criteria was evaluated retrospectively. 
Results 
1,072 (21.8%) athletes revealed an abnormal ECG based on the 2010 ESC 
recommendations. 11.2% athletes required echocardiography, 1.7% exercise stress 
test, 1.2% Holter, 1.2% cardiac MRI and 0.4% other tests. The Seattle and refined 
criteria reduced the number of positive ECGs to 6.0% and 4.3% respectively. 15 
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(0.3%) athletes were diagnosed with potentially serious cardiac disease using all 
three criteria. The overall cost of de-novo screening using the 2010 ESC 
recommendations amounted to $539,888, equating to $110 per athlete and $35,993 
per serious diagnosis. The Seattle and refined criteria reduced the cost to $92 and 
$87 per athlete screened and $30,251 and $28,510 per serious diagnosis 
respectively, representing a 21% cost saving per athlete screened. 
Conclusion 
Contemporary ECG interpretation criteria are associated with significant cost 
reductions for a de-novo screening program in athletes which may be cost 
permissive for some financially endowed sporting organisations. 
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INTRODUCTION 
Sudden cardiac death in sport is a rare but highly visible event and the identification 
of young athletes harbouring potentially serious cardiac disease is an important 
focus within the medical community. Pre-participation screening with a 12 lead 
electrocardiogram (ECG) is effective for detecting ion channel diseases and 
congenital accessory pathways and some electrical anomalies also raise suspicion 
of the main cardiomyopathies implicated in sudden cardiac death (1,2,3). The 30 
year old nationally sponsored Italian cardiac screening program with ECG has 
reported a substantial reduction in the prevalence of sudden cardiac death in young 
athletes since its inception (4). Although both the European Society of Cardiology 
(ESC) (5) and the International Olympic Committee (6) endorse ECG screening in 
athletes, an important concern regarding such practice is the unacceptably high false 
positive rate and subsequent cost generated by additional investigations to confirm 
or refute cardiac disease. The 2010 ESC recommendations for ECG interpretation in 
athletes are associated a false positive rate ranging from 9% to 22% (3,4,7,8).The 
Seattle criteria has significantly improved the specificity of ECG screening criteria for 
detecting cardiac disease associated with sudden cardiac death predominantly by 
accounting for specific benign repolarisation anomalies associated with black 
ethnicity and designating less conservative limits for an abnormal QT interval (2,7,8). 
More recent refined criteria have been associated with a further reduction in the false 
positive rate for detecting cardiac disease associated with sudden cardiac death 
without compromising sensitivity (7). Whether modification of the ECG interpretation 
criteria in young athletes is associated with a significant cost reduction has not been 
investigated.  
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This study compared the costs associated with additional investigations triggered by 
the ESC, Seattle and refined ECG criteria in a large cohort of young athletes in the 
United Kingdom (UK) undergoing cardiovascular screening for the first time. 
METHODS 
Setting 
The UK does not support a state-sponsored screening program in athletes. 
However, the charitable organisation Cardiac Risk in the Young established a 
cardiac screening program for young individuals in 1997 that also serves many 
professional sporting organisations in the UK (9). Up to 1500 athletes aged 14-35 
years from numerous regional or national sporting squads are assessed annually. 
The screening program is overseen by the senior author. The cost of the initial 
screening evaluation is incurred by the sporting organisation responsible for the 
athlete.  
Athletes 
Between 2011 and 2014, 5,374 consecutive athletes were screened as part of a 
mandatory requirement of their respective sporting organisations. 449 athletes been 
assessed previously as part of their clubs’ screening policy. In this group, 36 athletes 
(8%) had previously undergone further investigations beyond the ECG and cardiac 
disease was excluded.  We report data from 4,925 athletes who were previously 
unscreened with ECG. The dataset includes 1,026 athletes screened in 2011/12 who 
formed part of a previous investigation comparing the efficacy of major ECG 
interpretation criteria for detecting cardiac disease (7).  All athletes were initially 
evaluated by experienced sports cardiologists. Athletes were defined as individuals 
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competing in organized team or individual sports at regional, national, or 
international level with a high premium on athletic excellence. Ethnicity/race was 
determined by self-report. 
Preliminary Investigations in Athletes undergoing Pre-participation Screening 
Health Questionnaire 
The health questionnaire inquired about cardiac symptoms, past medical history, 
drug history, and family history of premature (<40 years old) cardiac disease or 
sudden cardiac death.  
Physical Examination 
Physical examination consisted of measurement of height, weight, radial and femoral 
pulses, brachial blood pressure measurements in the dominant arm, precordial 
examination at 450, and assessment for features of Marfan syndrome (10). Abnormal 
findings triggering further investigation included a blood pressure >140/90 mmHg on 
three consecutive occasions, radio-femoral delay, stigmata of Marfan Syndrome, a 
pathological murmur, widely split second heart sound or a third/fourth heart sound. 
Electrocardiography 
 A resting 12-lead ECG was performed using a Philips Pagewriter Trim III recorder 
(Philips, Bothell, Washington) with a paper speed of 25 mm/s and amplification of 0.1 
mV/mm. P-, Q-, R-, S-, and T-wave voltages; ST-segments; QRS duration; PR-
interval and QT-intervals were measured using callipers. The longest QT interval 
value was considered as the absolute QT and was corrected for heart rate with the 
Bazett’s formula (11) The 2010 ESC recommendations were initially used to interpret 
the ECG because they were the only recommendations available at the time of 
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initiation of the study (3). The Seattle criteria and refined criteria for ECG 
interpretation in athletes were applied to the cohort retrospectively (Table 1) (2,7).  
T-wave inversion in leads V1-3 in asymptomatic athletes aged >14<16 years old was 
considered a normal variant in the absence of a relevant family history irrespective to 
the ECG criterion used (12). Such individuals were advised to have a repeat ECG at 
age 16 years with view to further investigation if the juvenile pattern persisted.  
Further Investigations and Outcome 
The requirement for further investigations were determined by the screening sports 
cardiologists and was dependent on symptoms, relevant family history, abnormal 
physical examination or abnormal ECG. Athletes requiring secondary investigations 
were referred to hospitals within their geographic vicinity with a report that specified 
the abnormal findings, included the ECG, diagnosis in question, and a proposed 
investigation protocol based on our long standing experience of investigating 
athletes and patients with inherited cardiac disease (13). 
Concurrent with our clinical practice, we used less conservative limits for abnormal 
QT intervals than those considered by the 2010 ESC recommendations when 
advising the need for further investigations. This decision was based on high false 
positive rates and very low predictive value for the limits imposed by the 2010 ESC 
recommendations (1,14,15). Specifically, we recommended further investigations in 
asymptomatic male athletes with an isolated QT interval ≥ 470 msec and in 
asymptomatic females with a QT interval ≥ 480 msec, and an isolated QT interval ≤ 
320 msec in all athletes.   
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Secondary investigations were conducted by attending cardiologists and were aimed 
at confirming or refuting a diagnosis of cardiac disease. The ultimate decision 
relating to the type and number of secondary investigations was made by the 
attending cardiologist. Investigations included echocardiography, exercise stress 
testing, 24-hour ECG monitoring (Holter), 24 hour blood pressure monitoring, signal 
average ECG, cardiac magnetic resonance imaging (MRI), computed tomography, 
pharmacological provocation testing or electrophysiological studies. Serious cardiac 
diseases were defined as those implicated in exercise-related sudden cardiac death 
(16). Data relating to further investigations and the final diagnosis was obtained 
through communication with the club doctor using a questionnaire at 6 monthly 
intervals.  
Financial Analysis 
Costs were incurred in Great Britain pounds (£), but are presented in US dollars ($) 
with a currency exchange rate of £1=$1.52 at the time of manuscript preparation. 
The initial pre-participation screening tests (history, physical examination and ECG) 
were performed at a subsidised cost of $53 per athlete screened.  The costs of 
secondary investigations were calculated based on the 2014/2015 UK National 
Health Service tariff payment system (Table 2) (17). There is currently no national 
rebate for pharmacological testing for Brugada syndrome, or for 24 hour blood 
pressure monitoring or signal average ECG. Therefore we used the fee for these 
procedures at our institute for the analysis. The fee for genetic testing was obtained 
from a national molecular centre for clinical genetics in Oxford (UK) (18). The impact 
on cost after application of the Seattle and refine criteria was evaluated 
retrospectively. 
11 
 
Statistics 
Statistical analyses were performed using the SPSS software, version 17 (SPSS, 
Inc., Chicago, Illinois). Variables were tested for normality using the Kolmogorov-
Smirnov test. Group differences of normally distributed data were tested with the t-
test and expressed as mean (± standard deviation). Group differences of proportions 
were tested with the use of chi-square or Fisher's exact tests. Costs between ECG 
criteria were compared using paired rank sum testing. Significance was defined as p 
< 0.05.  
Ethics 
Ethical approval was granted by the Essex 2 Research Ethics Committee. Written 
consent was obtained from individuals ≥16 years of age and from a parent/ guardian 
for those <16 years of age.  
 
RESULTS 
Demographics 
Athletes were aged 19.9 ± 5 years (14-35 years). The majority were male (n=4,068; 
83%) and white (n=4,025; 85%). 444 athletes (9%) were of African or Afro-Caribbean 
origin and 276 (5%) consisted of other ethnicities. 4,230 (85.9%) athletes were aged 
≥16 years. Athletes competed in a total of 26 different sporting disciplines 
(predominantly rugby (53%), soccer (13%) and swimming (5%)) and exercised for 
15.6 ± 7 hours per week. 
History and Physical Examination 
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61 (1.2%) athletes revealed abnormalities on the health questionnaire. Of these, 43 
athletes reported symptoms that could have been consistent with cardiac disease 
according to the screening cardiologist (palpitations n=18, chest pain n=10, syncope 
n=8, and dyspnoea n=7) and 18 had a significant family history (cardiomyopathy 
n=6, channelopathy n=1, unexplained premature sudden cardiac death n=11). 18 
(0.4%) athletes had an abnormal physical examination (cardiac murmur n=12, blood 
pressure >140/90 n=4 and stigmata of Marfan syndrome n=2). 
ECG Interpretation 
1,072 (21.8%) athletes exhibited ≥1 ECG abnormality according to the 2010 ESC 
recommendations (inclusive of the original criteria for an abnormal QT interval) (3). 
295 (6.0%) athletes had an abnormal ECG with reference to  the Seattle criteria, 
equating to a 73% reduction compared to the 2010 ESC recommendations 
(p<0.0001).  Application of the refined criteria reduced the number of abnormal 
ECGs to 210 (4.3%). Compared to the 2010 ESC recommendations and Seattle 
criteria, this represented an 80% (p<0.0001) and 29% (p<0.0001) reduction in the 
number of abnormal ECGs respectively (Figure 1). 
The predominant factors in reducing the number of abnormal ECGs between the 
2010 ESC recommendations and the Seattle and refined criteria were the number of 
athletes considered to exhibit an abnormal QT interval (13.6% vs. 0.4%) or abnormal 
T-wave inversion (5.1% vs. 1.6% and 3.0% respectively). 
The prevalence of abnormal T-wave inversions according to the 2010 ESC, Seattle 
and refined criteria was 251 (5.1%), 81 (1.6%) and 149 (3.0%) respectively (Figure 
1). The lower number of athletes considered to have abnormal anterior T-wave 
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inversion (beyond V1 for refined and beyond V2 for Seattle) accounted for the 
difference between the Seattle and refined ECG criteria (0.8% vs. 2.2%; p<0.0001). 
 
Further Evaluation 
79 (1.6%) athletes required further investigations for symptoms, family history or 
abnormal physical examination and 502 (10.2%) athletes were referred for an 
abnormal ECG based on the 2010 ESC recommendations adapted for less 
conservative criteria for abnormal QT intervals. The difference in the actual number 
of athletes with an ECG abnormality (n=1,072) and the number of athletes referred 
for further investigations for an ECG abnormality (n=502) reflected our personal 
practice to not investigate asymptomatic athletes with an isolated long QT interval 
<470 msec (males) or <480 msec (females) (n=300), or a short QT interval 
>320<380 msec (n=270). Overall, 581 (11.8%) of the 4,925 athletes were referred 
for further investigations after preliminary screening. 
The authors received completed questionnaires relating to further investigations to 
confirm (or refute) diagnosis of disease in all 581 athletes. 550 (11.2%) athletes 
underwent transthoracic echocardiography, 85 (1.7%) underwent exercise stress 
testing, 59 (1.2%) underwent Holter monitoring, 61 (1.2%) underwent cardiac MRI 
and 18 (0.4%) underwent a combination of 24 hour blood pressure monitoring, signal 
average ECG, electrophysiological studies, trans-oesophageal echocardiography, 
computed tomography or pharmacological provocation testing for Brugada syndrome 
to confirm (or refute) diagnosis of cardiac disease (Table 2).  
14 
 
Application of the Seattle criteria and refined criteria would result in 374 (7.6%) and 
289 (5.9%) athletes requiring further investigation, representing a 35% and 50% 
reduction respectively compared to the 2010 ESC recommendations adapted for 
less conservative criteria for an abnormal QT interval (Table 2).  
None of the 449 athletes that had previously undergone cardiovascular screening 
required additional investigation following health questionnaire, physical examination 
and ECG. 
Identification of Cardiac Pathology 
Following further cardiac investigation, 15 (0.3%) athletes were diagnosed with 
cardiac pathology implicated in sudden cardiac death in young athletes. Specifically, 
6 athletes were diagnosed with hypertrophic cardiomyopathy, 3 with long QT 
syndrome and 6 with the Wolff-Parkinson-White Syndrome ECG pattern. All 15 
athletes were asymptomatic and diagnosed following an abnormal ECG irrespective 
of the ECG interpretation criterion used. The 6 athletes with hypertrophic 
cardiomyopathy displayed T-wave inversions in the lateral or inferior-lateral leads, 
and were diagnosed by a combination of echocardiography and cardiac MRI. The 3 
athletes with long QT syndrome were diagnosed on the basis of a prolonged QT 
interval (≥ 480msec) and exercise stress testing (Table 3).  
16 (0.3%) athletes were diagnosed with other structural cardiac abnormalities 
(bicuspid aortic valve n=12, atrial septal defect n=2, mitral valve prolapse n=2). Of 
these, 8 (50%) were diagnosed by abnormal physical examination whilst 8 (50%) 
were detected following investigation for an abnormal ECG by the 2010 ESC 
recommendations. The Seattle criteria would have failed to detect 2 athletes and the 
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refined criteria would not have identified 5 athletes with these conditions 
(supplemental table).  
Financial Analysis 
Preliminary Screening 
The initial cost of screening with history, physical examination and ECG was $53 per 
athlete which equates to a total cost of $261,025 for the 4,925 athletes screened. 
Evaluation after Pre-participation Screening 
The cost of evaluating 79 athletes with an abnormal history or examination 
amounted to $39,623. The cost of secondary investigations following an abnormal 
ECG according to the 2010 ESC recommendations adapted for less conservative 
criteria for abnormal QT interval was $239,240. Therefore, the overall cost of 
comprehensive cardiovascular evaluation for the entire cohort of previously 
unscreened athletes was $539,888 which equates to a cost of $110 per athlete 
screened and a cost of $17,416 per diagnosis of a cardiac condition and $35,993 per 
cardiac condition associated with sudden cardiac death. Adherence to the original 
2010 ESC recommendations for an abnormal QT interval would have resulted in an 
estimated cost of $157 per athlete on the assumption that all athletes would have 
had an exercise test and Holter monitor.  
Application of the Seattle criteria reduced the cost of secondary investigations to 
$153,120. The overall cost for the cohort would have been $453,768, equating to a 
cost of $92 per athlete screened and a cost of $15,647 per diagnosis of a cardiac 
condition and $30,251 per serious diagnosis. The $17 reduction per athlete screened 
represents a saving of 16% compared to screening with the 2010 ESC 
16 
 
recommendations (p<0.0001).The refined criteria reduced the cost of secondary 
investigations to $127,009 resulting in an overall cost of $427,657 and equating to a 
cost of $87 per athlete screened and a cost of $16,448 per diagnosis of a cardiac 
condition and $28,510 per diagnosis associated with sudden cardiac death. This 
figure represents a cost saving of $23 (21%) per athlete compared to the 2010 ESC 
recommendations (p<0.0001) and $5 (5%) per athlete compared to the Seattle 
criteria (p=0.114). Investigation for T-wave inversions accounted for 25% of the total 
cost of pre-participation screening with the 2010 ESC recommendations, 14% for the 
Seattle criteria and 21% of the refined criteria (Central illustration).  
Sensitivity Analysis 
We performed a sensitivity analysis investigating the impact on cost per athlete 
screened with the refined criteria with the following variables:  the initial non-invasive 
risk stratification tests (exercise stress test (n=10) and Holter (n=8)) at the time of 
diagnosis of serious disease, genetic testing for long QT syndrome (n=3) and 
hypertrophic cardiomyopathy (n=6), electrophysiological studies and radiofrequency 
ablation for 4 athletes with Wolff-Parkinson-White syndrome ECG pattern, and the 
inclusion of the 449 athletes who had previously undergone cardiovascular 
screening (Figure 2).  The inclusion of non-invasive risk stratification tests would 
result in an additional $1 per athlete screened.  Genetic testing for long QT 
syndrome and hypertrophic cardiomyopathy would result in a further $2 per athlete 
screened. Electrophysiological studies and radiofrequency ablation for Wolff-
Parkinson-White syndrome ECG pattern would add a further $2 per athlete. 
Conversely the inclusion of the athletes that had been previously screened would 
reduce the cost per athlete screened by $3.  
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DISCUSSION 
This study evaluated the financial implications of ECG based screening using 
different ECG interpretation criteria in almost 5,000 young athletes. Based on the 
diagnosis of a cardiac condition in 31 (0.6%) athletes, the overall cost of ECG 
screening with the 2010 ESC recommendations adapted for less conservative 
criteria for an abnormal QT interval equated to $110 per athlete screened and 
$17,416 per condition diagnosed ($35,993 per condition implicated in sudden 
cardiac death). The Seattle and refined criteria would reduce the cost per athlete 
screened by up to 21% without compromising the sensitivity for detecting athletes at 
risk of sudden cardiac death. The additional cost of non-invasive risk stratification at 
the time of diagnosis, gene testing and electrophysiological studies and 
radiofrequency ablation for Wolff-Parkinson-White syndrome ECG pattern amount to 
an additional $5 per athlete. This figure represents a small cost increment of 5% 
based on the refined criteria and is still $18 (16%) cheaper than the cost of diagnosis 
alone using the adapted 2010 ESC recommendations.  
Trends in Investigations 
Following preliminary assessment, 11.2% of the athletes required transthoracic 
echocardiography, 1.7% exercise stress testing, 1.2% Holter monitoring, 1.2% 
cardiac MRI and 0.4% required other tests respectively (Table 2). To our knowledge, 
there are only three studies describing the extent of secondary investigations 
following abnormalities on history, physical examination or ECG (4,19,20). In the 
Veneto region of Italy, 9% of 42,386 athletes required further investigation due to an 
ECG abnormality; overall further investigations included echocardiography in 9.2%, 
exercise stress testing in 3.1%, Holter monitoring in 1.2%, and a combination of 
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cardiac MRI or more invasive testing such as electrophysiological studies or 
angiography in 0.2%.  Whilst our cohort differs from the Italian study in that 
secondary investigations were not limited to a single centre, the overall trend is 
similar. The higher rate of cardiac MRI in our study can be explained by the 
increasing availability and application of this test compared to the Italian study in 
2004 (4).  
Compared to the 2010 ESC recommendations adapted for less conservative limits 
for abnormal QT intervals, application of more contemporary ECG interpretation 
guidelines would reduce the number of athletes requiring further investigation 
following screening by up to 50% which would significantly impact health resources 
(Table 2). Specifically, the refined criteria would have resulted in 50% reduction in 
the number of echocardiograms, 12% reduction in the number of exercise tests, 8% 
reduction in Holter monitors, and 18% reduction in the number of cardiac MRI scans 
that would need to be performed to confirm (or refute) the diagnosis of cardiac 
disease.  
Cost Analysis 
Our study was intended to report the impact on the type and cost of further 
investigations following the modification of ECG criteria rather than assess the cost-
effectiveness of cardiac screening. Our findings are comparable with a significantly 
smaller Swiss study of just over 1000 athletes who were also screened with ECG 
that was interpreted on the basis of the 2010 ESC recommendations with several 
modifications similar to the Seattle criteria (19). The study reported a cost of $146 
per athlete screened and $39,119 per serious condition detected. Unlike our study, 
all athletes self-referred and were exclusively white. Furthermore, the indications for 
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additional investigations were consensually established by only two cardiologists, 
which does not reflect real-life practice. Another study from Qatar also reported the 
costs relating to ECG screening in 1,628 athletes also using recommendations 
resembling the Seattle criteria (20). The cost per athlete was significantly higher than 
our study and equated to $265. Besides a significantly smaller sample size, the 
study was not comparable to ours in several aspects. Over 50% of athletes were of 
Arabic origin which is not representative of athletes in the Western world. All 
investigations were conducted in a single centre and therefore not representative of 
nationwide screening of young athletes. 
Compared to the 2010 ESC recommendations, the modifications in the Seattle and 
refined criteria equate to a cost advantage and would reduce the overall cost of 
screening by 16% and 21% per athlete respectively. Based on our sensitivity 
analysis, these savings may allow organisations to afford the additional costs of non-
invasive risk stratification tests at time of diagnosis, gene testing and radiofrequency 
ablation for the Wolff-Parkinson-White syndrome ECG pattern.   Although the refined 
criteria were associated with a reduction in the number of abnormal ECGs compared 
to the Seattle criteria, this advantage did not translate to a significant cost saving. 
The discrepancy can be attributed to the differences in the interpretation of anterior 
T-wave inversion between the two criteria (2,7).T-wave inversion in the right 
precordial leads is associated with arrhythmogenic right ventricular cardiomyopathy, 
which invariably requires a plethora of cardiac investigations including cardiac MRI, 
signal averaged ECG, Holter monitor and exercise stress test for diagnosis (21). In 
white athletes, the refined criteria recommend investigation in athletes with anterior 
T-wave inversion beyond V1 whereas the Seattle criteria recommend further 
investigation only if T-wave inversion extends beyond V2 (Table 1). The added costs 
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associated with investigating a greater proportion of athletes with anterior T-wave 
inversion negate the positive impact of a lower number of abnormal ECGs with the 
refined criteria.  
The 2010 ESC recommendations resulted in the detection of a higher number of 
minor congenital abnormalities compared with contemporary criteria but we believe 
this was fortuitous. Although left atrial enlargement or left axis deviation was present 
on the ECG in a significant proportion of such athletes, we have previously 
demonstrated that there is no difference in the prevalence of minor congenital 
cardiac abnormalities in athletes and healthy controls with either of these ECG 
anomalies compared to athletes with normal ECGs (22). Even after allowance for 
these diagnoses, the cost of screening remained lower with contemporary criteria. 
Cost Issues and Clinical Implications to the Larger UK Athlete Population 
Based on the Active People Survey, a national survey of sports participation, 
3,245,400 young people (14-35 years) participated in competitive sport in 2014/15 
(23). Extrapolation of our costs to these athletes means that a de novo screening 
programme for all athletes in the UK would cost $356,994,000 and detect a 
substantial number (9,736 athletes) harbouring conditions that are associated with 
exercise-related sudden cardiac death using the 2010 ESC recommendations 
(adapted for less conservative criteria for abnormal QT intervals). Application of the 
Seattle and refined criteria would cost $298,576,800 and $282,349,800 respectively, 
equating to a huge saving of approximately $58 to 75 million. These estimates do not 
take into consideration for the invariable cost reduction of screening the same cohort 
during subsequent years. 
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Whether these costs provide a feasible solution for all athletes is debatable. 
Application of the most specific ECG interpretation criteria (refined criteria) would 
translate to a cost of nearly $29,000 per diagnosis of a potentially serious cardiac 
condition and may be acceptable for lucrative organisations. However, considering 
the large number of exercising young individuals and the low incidence of exercise-
related sudden cardiac death, it is arguable that the cost of nationwide screening 
may be excessive for less financially endowed sporting organisations, and could be 
invested in improving training and facilities for cardiopulmonary resuscitation 
(24,25,26).  
Study Limitations 
The cost analysis was based on subsidized amounts for preliminary assessment 
($53 per athlete) and relatively modest costs of secondary investigations in the UK 
National Health Service which may be considerably cheaper compared to other 
healthcare models. Nevertheless, the systematic methodology of investigating a 
large number of athletes by experts in sports cardiology should enable a relatively 
precise estimate of the number of additional investigations required to other Western 
populations. Secondary investigations were at the discretion of the attending 
cardiologist and may have been influenced by personal clinical practice as would be 
expected in real-life clinical situations. It is prudent to emphasise that these costs 
relate solely to the detection of new cardiac conditions and do not account for any 
downstream costs of management and on-going clinical surveillance of affected 
athletes.  
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Finally, data relating to secondary investigations in athletes with abnormal history, 
physical examination or ECG relied solely on information provided by club doctors 
and may be subject to recall bias. 
 
CONCLUSIONS 
Contemporary ECG interpretation guidelines are associated with a cost reduction of 
up to 21% without compromising sensitivity to detect serious cardiac disease. These 
results represent a welcome saving for sporting organisations equipped with the 
infrastructure and expertise for cardiac screening in athletes. 
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CLINICAL PERSPECTIVES 
Competency in Medical Knowledge 
Modification of ECG interpretation guidelines improves specificity for detecting 
serious cardiac disease and is associated with a 21% reduction in the cost of 
cardiovascular screening in young athletes. 
Translational Outlook 
Sequential long term follow-up of young athletes is required to evaluate the impact of 
ECG modification on the cost effectiveness of screening with ECG. 
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Figure Legends 
Figure 1:  
Title: ECG abnormalities with reference to the 2010 ESC recommendations, Seattle  
criteria and refined criteria. 
Caption: Differences in criteria for an abnormal QT interval and abnormal T-wave  
inversion are responsible for the lower number of abnormal ECGs with the Seattle  
criteria and refined criteria compared to the 2010 ESC recommendations.  
 
Central illustration:  
Title: The financial impact of modification of ECG interpretation criteria in young  
athletes. 
Key: ǂ adapted for less conservative criteria for an abnormal QT interval 
Caption: Compared to the 2010 ESC recommendations, the costs for subsequent  
investigation following an abnormal ECG with the Seattle criteria and refined criteria  
are reduced by 21%. 
 
Figure 2: 
Title: Sensitivity analysis reporting the impact of several variables on the cost per  
athlete screened with the refined criteria. 
Key: HCM=hypertrophic cardiomyopathy, EPS=electrophysiological study,  
LQTS=long QT syndrome, WPW= Wolff-Parkinson-White syndrome  
Caption: Risk stratification tests at diagnosis, genetic testing and electrophysiological 
studies ± ablation for Wolff-Parkinson-White ECG pattern raise costs by $5 per  
athlete screened. Conversely, inclusion of previously screened athletes in the 
analysis reduces the cost per by $3 per athlete screened. 
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Tables 
Table 1: Definition of ECG abnormalities in athletes according to the 2010 ESC  
Recommendations (3), Seattle criteria (2) and refined criteria (7). 
All 3 criteria ST segment depression 
Pathological Q-waves 
Complete left bundle branch block 
Wolff-Parkinson-White syndrome pattern 
Brugada-like early repolarisation pattern 
Premature ventricular contractions 
Atrial or ventricular arrhythmia 
 
2010 ESC recommendations  T-wave inversion 
Long QT interval >440 msec (male) or >460 msec (female) 
Short QT interval <380 msec 
Right ventricular hypertrophy 
Right or left axis deviation 
Right or left atrial enlargement 
Complete right bundle branch block 
Non-specific intraventricular delay (QRS >120 msec) 
 
Seattle criteria T-wave inversion beyond V2 in white athletes 
T-wave inversion beyond V4 in black athletes 
Long QT interval ≥470 msec (male) or ≥480 msec (female) 
Short QT interval ≤320 msec 
Right ventricular hypertrophy (in presence of right axis 
deviation) 
Left axis deviation 
Right or left atrial enlargement 
Non-specific intraventricular delay (QRS ≥140 msec) 
 
Refined criteria T-wave inversion beyond V1 in white athletes 
T-wave inversion beyond V4 in black athletes 
Long QT interval ≥470 msec (male) or ≥480 msec (female) 
Short QT interval ≤320 msec 
Complete right bundle branch block 
Non-specific intraventricular delay (QRS >120 msec) 
 
Borderline variants (requiring investigation if >1 present) 
T-wave inversion up to V4 in black athletes 
Right ventricular hypertrophy 
Left axis deviation 
Right axis deviation 
Right atrial enlargement 
Left atrial enlargement  
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Table 2: Cost and frequency of additional investigations following abnormality in 
history and physical examination, or ECG. 
 
 Cost ($) History and 
physical 
examination 
        N (%) 
ECG interpreted 
with 2010 ESC 
recommendations 
N (%) 
ECG interpreted 
with Seattle 
criteria  
N (%) 
ECG interpreted 
with refined 
criteria 
N (%) 
Hospital appointment for 
further evaluation and 
additional investigations 
249 79 (1.6%) 502 (10.2%) 295 (6.0%) 210 (4.3%) 
Transthoracic 
echocardiography 
112 66 (1.3%) 484 (9.8%) 274 (5.6%) 197 (4.0%) 
Exercise stress test 258 12 (0.2%)  73 (1.5%) ‡ 
10 (0.2%) † 
58 (1.2%) ‡ 
10 (0.2%) † 
63 (1.3%) ‡ 
10 (0.2%) † 
24 hour ECG (Holter) 258 12 (0.2%) 47 (1.0%) ‡ 
8 (0.2%) † 
38 (0.8%) ‡ 
8 (0.2%) † 
42 (0.9%) ‡ 
8 (0.2%) † 
Cardiac magnetic resonance 
imaging (MRI) 
319 1 (0.02%) 60 (1.1%) 45 (0.9%) 49 (1.0%) 
24 hour blood pressure 
monitoring 
258 4 (0.08%) 1 (0.02%) 1 (0.02%) 1 (0.02%) 
Signal average ECG 40 0 4 (0.08%) 2 (0.04%) 4 (0.08%) 
Electrophysiological study (± 
ablation) 
3026 1 (0.02%) 3 (0.06%) ‡ 
4 (0.08%) * 
3 (0.06%) ‡ 
4 (0.08%) * 
3 (0.06%) ‡ 
4 (0.08%) * 
Cardiac computed tomography  167 1 (0.02%) 0 0 0 
Transoesophageal 
echocardiography 
438 0 1 (0.02%) 1 (0.02%) 1 (0.02%) 
Provocation testing for 
Brugada syndrome 
608 3 (0.06%) 0 0 0 
Genetic testing for long QT 
syndrome and hypertrophic 
cardiomyopathy 
912 0 9 (0.2%) 9 (0.2%) 9 (0.2%) 
 
Key: ‡ diagnostic indication, †non-invasive risk stratification indication, * risk 
stratification and treatment for Wolff-Parkinson-White syndrome ECG pattern
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Table 3: Characteristics of athletes diagnosed with disease implicated in sudden cardiac death 
      Pathology Age/Gender Ethnicity Sport H+P abnormality ECG abnormality Diagnostics Risk 
stratification 
Other Outcome 
       HCM 34/Male Caucasian Ballet Nil Lateral TWI ECHO, MRI EST, Holter Gene test Retired 
       HCM 35/Male Caucasian Soccer Nil Inferior-lateral TWI ECHO, MRI EST Gene test Retired 
       HCM 33/Male Caucasian Rugby Nil Lateral TWI ECHO, MRI EST Gene test Retired 
       HCM 24/Male Caucasian Rugby Nil Inferior-Lateral TWI ECHO, MRI EST Gene test Playing against  
medical advice 
       HCM 19 /Male Afro-Caribbean Cricket Nil Inferior-Lateral TWI ECHO, MRI - Gene test Playing against  
medical advice 
       HCM 14/Male Caucasian Swimming Nil Inferior-Lateral TWI ECHO, MRI EST Gene test Playing against 
medical advice 
       LQTS 16/Female Caucasian Netball Nil QTc 480msec 
T-wave notching 
ECHO, EST Holter Gene test Playing against  
medical advice 
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       LQTS 15/Male Caucasian Swimming Nil QTc 510msec 
T-wave notching 
ECHO, EST  Holter Gene test Retired 
       LQTS 27/Male Afro-Caribbean Soccer Nil QTc 550msec 
T-wave notching 
ECHO, EST  Holter Gene test Playing against 
medical advice 
WPW ECG 
pattern 
14/Female Caucasian Swimming Nil Short PR interval 
Delta wave 
- - - Conservative 
management 
WPW ECG 
pattern 
15/Male Afro-Caribbean Soccer Nil Short PR interval 
Delta wave 
- EST, Holter, 
EPS 
- Treated with 
radiofrequency 
ablation 
WPW ECG 
pattern 
16/Male Caucasian Rugby Nil Short PR interval 
Delta wave 
- EST, Holter. 
EPS 
- Treated with 
radiofrequency 
ablation 
WPW ECG 
pattern 
17/Female Afro-Caribbean Cricket Nil Short PR interval 
Delta wave 
- EST - Conservative 
management 
 
WPW ECG 
pattern 
17/Male Caucasian Rugby Nil Short PR interval 
Delta wave 
Inferior TWI 
ECHO EST, Holter, 
EPS 
- Treated with 
radiofrequency 
ablation 
WPW ECG 
pattern 
20/Male Caucasian Rugby Nil Short PR interval 
Delta wave 
- EST, Holter, 
EPS 
- Treated with 
radiofrequency 
ablation 
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Key: ECHO= echocardiogram, EST=exercise stress test, EPS= electrophysiology study, H+P=history and physical examination, 
HCM=hypertrophic cardiomyopathy, LQTS=long QT syndrome, MRI=magnetic resonance imaging, msec= milliseconds, QTc= QT 
interval corrected for heart rate, TWI=T-wave inversion, WPW= Wolff-Parkinson-White syndrome 
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